MCID: IMP006
MIFTS: 40

Impulse Control Disorder malady

Categories: Mental diseases

Aliases & Classifications for Impulse Control Disorder

Aliases & Descriptions for Impulse Control Disorder:

Name: Impulse Control Disorder 12 14
Disruptive, Impulse Control, and Conduct Disorders 42 69

Classifications:



External Ids:

Disease Ontology 12 DOID:10937
ICD10 33 F63.9
ICD9CM 35 312.30
MeSH 42 D007174
NCIt 47 C34723
UMLS 69 C0021122

Summaries for Impulse Control Disorder

Disease Ontology : 12 A disease of mental health that involves a failure to resist an impulsive act or behaviour that may be harmful to self or others.

MalaCards based summary : Impulse Control Disorder, also known as disruptive, impulse control, and conduct disorders, is related to pyromania and kleptomania. An important gene associated with Impulse Control Disorder is ANKK1 (Ankyrin Repeat And Kinase Domain Containing 1), and among its related pathways/superpathways are Dopamine-DARPP32 Feedback onto cAMP Pathway and Circadian rythm related genes. The drugs Carbidopa and Dopamine have been mentioned in the context of this disorder. Affiliated tissues include testes, eye and brain, and related phenotype is Increased shRNA abundance (Z-score > 2).

Wikipedia : 71 Impulse control disorder (ICD) is a class of psychiatric disorders characterized by impulsivity –... more...

Related Diseases for Impulse Control Disorder

Diseases related to Impulse Control Disorder via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 52)
id Related Disease Score Top Affiliating Genes
1 pyromania 31.6 DRD2 DRD3 DRD4
2 kleptomania 11.2
3 trichotillomania 11.2
4 pathological gambling 11.1
5 kluver-bucy syndrome 10.8
6 intermittent explosive disorder 10.8
7 apperceptive agnosia 10.2 ANKK1 DRD2
8 teratoma with malignant transformation 10.2 DRD2 DRD3
9 strongyloidiasis 10.2 ANKK1 DRD2
10 fallopian tube disease 10.1 DLGAP3 SLITRK1
11 ischemic neuropathy 10.1 DRD2 DRD3
12 colorectal adenocarcinoma 10.1 DRD2 DRD4
13 suppurative periapical periodontitis 10.1 DRD2 DRD3
14 transmitted_by 10.1 DRD2 DRD3
15 hypoglycemia 10.1 ANKK1 DRD2 DRD3
16 18p deletion syndrome 10.1 ANKK1 DRD2 DRD4
17 dyspepsia 10.1 CLNK SLITRK1
18 sphenoorbital meningioma 10.0 DRD2 DRD3 DRD4
19 c8 deficiency, type ii 10.0 DRD2 DRD3 DRD4
20 cytomegalic congenital adrenal hypoplasia 10.0 DRD2 DRD3 DRD4
21 mucinous adenocarcinoma 10.0 DRD2 DRD3 DRD4
22 rectosigmoid junction neoplasm 10.0 DRD2 DRD4 SLITRK1
23 hypereosinophilic syndrome 10.0 DRD2 DRD3 DRD4
24 chronic conjunctivitis 10.0 DRD2 DRD3 DRD4
25 aortic valve disease 2 10.0 DRD2 DRD4 SLITRK1
26 microcephaly 13, primary, autosomal recessive 10.0 DRD2 DRD3 DRD4
27 usher syndrome 10.0 DRD2 DRD3
28 ellis-van creveld syndrome 9.9 DRD2 DRD3 DRD4
29 nystagmus 4, congenital, autosomal dominant 9.9 CLNK DLGAP3 SLITRK1
30 restless legs syndrome 9.9
31 cecal benign neoplasm 9.9 ANKK1 DRD2 DRD3 DRD4
32 alopecia 9.9 ANKK1 DRD2 DRD3 DRD4
33 preeclampsia/eclampsia 5 9.9 ANKK1 DRD2 DRD3 DRD4
34 paraphilia disorder 9.9 DRD2 DRD3 DRD4
35 obsessive-compulsive disorder 9.8
36 drug addiction 9.8
37 personality disorder 9.8 DRD2 DRD3 DRD4 GRN SLITRK1
38 retinoblastoma 9.7 DLGAP3 DRD2 DRD3 DRD4 SLITRK1
39 bipolar i disorder 9.6
40 perry syndrome 9.6
41 epilepsy 9.6
42 dermatitis 9.6
43 gilles de la tourette syndrome 9.6
44 dystonia 9.6
45 rem sleep behavior disorder 9.6
46 bipolar disorder 9.6
47 intellectual disability 9.6
48 alexithymia 9.6
49 basal ganglia calcification 9.6
50 social phobia 9.6

Comorbidity relations with Impulse Control Disorder via Phenotypic Disease Network (PDN):


Schizophreniform Disorder

Graphical network of the top 20 diseases related to Impulse Control Disorder:



Diseases related to Impulse Control Disorder

Symptoms & Phenotypes for Impulse Control Disorder

GenomeRNAi Phenotypes related to Impulse Control Disorder according to GeneCards Suite gene sharing:

26
id Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Increased shRNA abundance (Z-score > 2) GR00366-A-126 9.6 DRD4
2 Increased shRNA abundance (Z-score > 2) GR00366-A-127 9.6 DRD4
3 Increased shRNA abundance (Z-score > 2) GR00366-A-132 9.6 DRD4 CLNK DRD3
4 Increased shRNA abundance (Z-score > 2) GR00366-A-137 9.6 DRD3
5 Increased shRNA abundance (Z-score > 2) GR00366-A-158 9.6 CLNK
6 Increased shRNA abundance (Z-score > 2) GR00366-A-159 9.6 DRD3
7 Increased shRNA abundance (Z-score > 2) GR00366-A-161 9.6 DRD3
8 Increased shRNA abundance (Z-score > 2) GR00366-A-166 9.6 DRD3
9 Increased shRNA abundance (Z-score > 2) GR00366-A-172 9.6 DRD4
10 Increased shRNA abundance (Z-score > 2) GR00366-A-214 9.6 CLNK
11 Increased shRNA abundance (Z-score > 2) GR00366-A-35 9.6 DRD3
12 Increased shRNA abundance (Z-score > 2) GR00366-A-51 9.6 DRD3
13 Increased shRNA abundance (Z-score > 2) GR00366-A-52 9.6 CLNK
14 Increased shRNA abundance (Z-score > 2) GR00366-A-56 9.6 DRD4
15 Increased shRNA abundance (Z-score > 2) GR00366-A-67 9.6 DRD3
16 Increased shRNA abundance (Z-score > 2) GR00366-A-8 9.6 CLNK
17 Increased shRNA abundance (Z-score > 2) GR00366-A-85 9.6 DRD3

Drugs & Therapeutics for Impulse Control Disorder

Drugs for Impulse Control Disorder (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 276)
id Name Status Phase Clinical Trials Cas Number PubChem Id
1
Carbidopa Approved Phase 4 28860-95-9 34359 38101
2
Dopamine Approved Phase 4,Phase 3,Phase 2,Phase 1 51-61-6, 62-31-7 681
3
Levodopa Approved Phase 4,Phase 1,Phase 2 59-92-7 6047
4
Methylphenidate Approved, Investigational Phase 4,Phase 1,Phase 2 113-45-1 4158
5
Topiramate Approved Phase 4,Phase 2 97240-79-4 5284627
6
Nicotine Approved Phase 4,Phase 2,Phase 1 54-11-5 942 89594
7
Guanfacine Approved, Investigational Phase 4 29110-47-2 3519
8
Ethanol Approved Phase 4,Phase 3,Phase 2 64-17-5 702
9
Naltrexone Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1 16590-41-3 5360515
10
Pramipexole Approved, Investigational Phase 4 104632-26-0 59868 119570
11
Ropinirole Approved, Investigational Phase 4 91374-20-8, 91374-21-9 5095 497540
12
Citalopram Approved Phase 4 59729-33-8 2771
13
Sertraline Approved Phase 4,Phase 2 79617-96-2 68617
14
Acamprosate Approved, Investigational Phase 4 77337-76-9 71158
15
Selegiline Approved, Investigational, Vet_approved Phase 4 14611-51-9 26757 5195
16
Olanzapine Approved, Investigational Phase 4,Phase 3 132539-06-1 4585
17
Valproic Acid Approved, Investigational Phase 4 99-66-1 3121
18
Budesonide Approved Phase 4 51333-22-3 63006 5281004
19
Nitric Oxide Approved Phase 4,Phase 2 10102-43-9 145068
20
Cetirizine Approved Phase 4 83881-51-0 2678
21
Histamine Approved, Investigational Phase 4 75614-87-8, 51-45-6 774
22
Mannitol Approved, Investigational Phase 4 69-65-8 453 6251
23
Methyltestosterone Approved Phase 4 58-18-4 6010
24
Testosterone Approved, Investigational Phase 4 58-22-0 6013
25
Aspirin Approved, Vet_approved Phase 4 50-78-2 2244
26
Neostigmine Approved, Vet_approved Phase 4 59-99-4 4456
27
Rocuronium Approved Phase 4 119302-91-9, 143558-00-3 441290
28
Naratriptan Approved, Investigational Phase 4 143388-64-1, 121679-13-8 4440
29 Antiparkinson Agents Phase 4,Phase 3,Phase 2,Phase 1
30 Aromatic Amino Acid Decarboxylase Inhibitors Phase 4
31 Autonomic Agents Phase 4,Phase 3,Phase 2,Phase 1
32 Dopamine Agents Phase 4,Phase 3,Phase 2,Phase 1
33 Dopamine agonists Phase 4,Phase 3,Phase 2
34 Neurotransmitter Agents Phase 4,Phase 3,Phase 2,Phase 1
35 Peripheral Nervous System Agents Phase 4,Phase 3,Phase 2,Phase 1
36 Protective Agents Phase 4,Phase 3,Phase 2,Phase 1
37 Central Nervous System Stimulants Phase 4,Phase 2,Phase 1
38 Dopamine Uptake Inhibitors Phase 4,Phase 2,Phase 1
39 Neurotransmitter Uptake Inhibitors Phase 4,Phase 3,Phase 2,Phase 1
40 Anticonvulsants Phase 4,Phase 2
41 Anti-Obesity Agents Phase 4,Phase 2
42 Neuroprotective Agents Phase 4,Phase 3,Phase 2
43 Cholinergic Agents Phase 4,Phase 3,Phase 2,Phase 1
44 Nicotinic Agonists Phase 4,Phase 2,Phase 1
45 Adrenergic Agents Phase 4,Phase 3,Phase 2,Phase 1
46 Adrenergic Agonists Phase 4,Phase 3
47 Adrenergic alpha-2 Receptor Agonists Phase 4,Phase 3
48 Adrenergic alpha-Agonists Phase 4,Phase 3
49 Antihypertensive Agents Phase 4,Phase 2
50 Antiemetics Phase 4,Phase 3,Phase 2

Interventional clinical trials:

(show top 50) (show all 300)
id Name Status NCT ID Phase
1 Remission of ICD by Switching Dopamine Agonist to Levodopa/Carbidopa Unknown status NCT01683253 Phase 4
2 Methylphenidate in ADHD With Trichotillomania Unknown status NCT00552266 Phase 4
3 Topiramate in the Treatment of Pathological Gambling Unknown status NCT00245583 Phase 4
4 Nicotine Treatment of Impulsivity in Parkinson's Disease Unknown status NCT01216904 Phase 4
5 Intuniv vs Placebo in the Treatment of Childhood Intermittent Explosive Disorder Unknown status NCT02048241 Phase 4
6 Naltrexone for Impulse Control Disorders in Parkinson's Disease Completed NCT01052831 Phase 4
7 Escitalopram for the Treatment of Self-Injurious Skin Picking Completed NCT00115011 Phase 4
8 Sertraline and Habit Reversal in the Treatment of Patients With Trichotillomania Completed NCT00118014 Phase 4
9 Acamprosate in the Treatment of Pathological Gambling Completed NCT00571103 Phase 4
10 Efficacy of Orally Disintegrating Selegiline in Parkinson's Patients Experiencing Adverse Effects With Dopamine Agonists Completed NCT00443872 Phase 4
11 Olanzapine in the Treatment of Hair Pulling (Trichotillomania) Completed NCT00182507 Phase 4
12 Treatment of Pathological Gambling With Naltrexone Pharmacotherapy and Brief Intervention Completed NCT01528007 Phase 4
13 A Randomized, Double-blind, Active (Pramipexole 0.5 mg Tid) and Placebo Controlled, Study of Pramipexole Given 0.5 mg and 0.75 mg Bid Over 12-week Treatment in Early Parkinson's Disease (PD) Patients Completed NCT00402233 Phase 4
14 Valproic Acid Sodium Salt in Bipolar Disorder Completed NCT00431522 Phase 4
15 Pharmacological Effect of Lysozyme for Chronic Obstructive Pulmonary Disease and Asthma With Sputum Symptom Completed NCT01715493 Phase 4
16 Chronic Obstructive Pulmonary Disease Endpoints Study Completed NCT00358358 Phase 4
17 Effect of Symbicort on HAT and HDAC in Sputum Macrophages of COPD Completed NCT00291408 Phase 4
18 Study of Bronchodilation Effects of Cetirizine Completed NCT01781507 Phase 4
19 Ultra-long Acting Bronchodilator Therapy in Asthmatics Completed NCT02039011 Phase 4
20 Small Airway Function of Fluticasone/Formoterol (Flutiform®) and Fluticasone/Salmeterol Completed NCT02491970 Phase 4
21 Physiological and Psychological Effects of Testosterone During Severe Energy Deficit and Recovery Recruiting NCT02734238 Phase 4
22 Radiofrequency in the Treatment of Barrett's Oesophagus Recruiting NCT02558504 Phase 4
23 Targeted Small Airways Therapy in Persistent Asthma Recruiting NCT01894048 Phase 4
24 Sugammadex vs. Placebo to Prevent Residual Neuromuscular Block in the Post--‐Anesthesia Care Unit Recruiting NCT02822001 Phase 4
25 Inhaler Lung Deposition in Chronic Obstructive Pulmonary Disease (COPD) Active, not recruiting NCT01721291 Phase 4
26 Efficacy of a Triptan in the Treatment of Hostility and Aggression Among Convicts With a Psychiatric Treatment Order Terminated NCT00282165 Phase 4
27 Effect of Tiotropium Inhalation Capsules on Exercise Tolerance, Daily Activity and Dyspnoea in Patients With Chronic Obstructive Pulmonary Disease (COPD) Participating in 3 Weeks of Pulmonary Rehabilitation Terminated NCT02172508 Phase 4
28 Essential Fatty Acids in Adult ADHD Unknown status NCT01798381 Phase 3
29 The Efficacy of Steroid Therapy in Vestibular Neuritis Unknown status NCT02098330 Phase 3
30 Rehabilitation With Patterned Electrical Neuromuscular Stimulation for Patients With Patellofemoral Pain Unknown status NCT02441712 Phase 2, Phase 3
31 Drug Treatment for Pathologic Gambling Disorder Completed NCT00053677 Phase 3
32 Nalmefene Gambling Study: Study of Nalmefene HCl in the Treatment of Pathological Gambling Completed NCT00132119 Phase 2, Phase 3
33 Minimal and Brief Treatments for Pathological Gamblers Completed NCT00203645 Phase 3
34 Safety and Efficacy Trial of Olanzapine in Outpatients With Pathological Gambling Completed NCT00438776 Phase 3
35 Study to Determine Whether There Are Any Cognitive or Motor Effects From Taking the Medicine Risperidone. Completed NCT00399698 Phase 3
36 Allopurinol for Mania: A Randomized Trial Administering Allopurinol vs. Placebo as add-on to Mood Stabilizers and/or Antipsychotics in Patients in a Bipolar Manic Episode Completed NCT01092221 Phase 3
37 A Cardiac Safety Study of Galantamine in the Treatment of Alzheimer's Disease. Completed NCT00309725 Phase 3
38 Non-Invasive Targeted Electronic Pain Control Device ("Biowave System") Versus Transcutaneous Electrical Nerve Stimulation (TENS) for the Symptomatic Treatment of Chronic Low Back Pain Completed NCT00277797 Phase 3
39 Effects of Kneehab 12-week Peri-operative Total Knee Arthroplasty Completed NCT01096524 Phase 3
40 Defocused Shock Wave Therapy for Chronic Wounds Completed NCT02410447 Phase 3
41 Safety and Efficacy of Oral Fampridine-Sustained Release (SR) for the Treatment of Spasticity Resulting From Spinal Cord Injury Completed NCT01683838 Phase 3
42 Safety and Efficacy of Oral Fampridine-SR for the Treatment of Spasticity Resulting From Spinal Cord Injury Completed NCT00041717 Phase 3
43 A Pilot Study Evaluating a Multidisciplinary Chronic Pain Group Therapy in a Primary Care Setting Completed NCT01517256 Phase 3
44 Childhood Asthma Research and Education (CARE) Network Trial - Best Add-On Therapy Giving Effective Response (BADGER) Completed NCT00395304 Phase 3
45 A Study in Patients With Asthma Completed NCT01570478 Phase 3
46 Childhood Asthma Research and Education (CARE) Network Trial - Treating Children to Prevent Exacerbations of Asthma (TREXA) Completed NCT00394329 Phase 3
47 Dopamine Agonist Treatment of Non-functioning Pituitary Adenomas Recruiting NCT02288962 Phase 3
48 Validation of a Test System for Development of Medications for Alcoholism Recruiting NCT02652585 Phase 3
49 A Study to Evaluate the Effect of Fluticasone/Formoterol Breath Actuated Inhaler (BAI) or Relvar® Ellipta® DPI on Ventilation Heterogeneity in Asthma Recruiting NCT02753712 Phase 3
50 Phase 3 Clinical Trial: D-methionine to Reduce Noise-Induced Hearing Loss (NIHL) Recruiting NCT01345474 Phase 3

Search NIH Clinical Center for Impulse Control Disorder

Cochrane evidence based reviews: disruptive, impulse control, and conduct disorders

Genetic Tests for Impulse Control Disorder

Anatomical Context for Impulse Control Disorder

MalaCards organs/tissues related to Impulse Control Disorder:

39
Testes, Eye, Brain

Publications for Impulse Control Disorder

Articles related to Impulse Control Disorder:

(show top 50) (show all 57)
id Title Authors Year
1
Risk of Gambling Disorder and Impulse Control Disorder With Aripiprazole, Pramipexole, and Ropinirole: A Pharmacoepidemiologic Study. ( 27930495 )
2017
2
Impulse control disorder, lysosomal malfunction and ATP13A2 insufficiency in Parkinsonism. ( 27997702 )
2017
3
Association between REM sleep behaviour disorder and impulse control disorder in patients with Parkinson's disease. ( 27087472 )
2016
4
Editorial: Exploring Gender and Sex Differences in Behavioral Dyscontrol: From Drug Addiction to Impulse Control Disorders. ( 26941657 )
2016
5
Impaired learning of punishments in Parkinson's disease with and without impulse control disorder. ( 27848033 )
2016
6
Tattooing as a Symptom of Impulse Control Disorder in a Parkinsonian Patient With Pramipexole. ( 27749676 )
2016
7
Impulse control disorder related behaviours during long-term rotigotine treatment: a post hoc analysis. ( 27425586 )
2016
8
18F-FDG -PET Correlates of Impulse Control Disorder In A Diabetic Patient. ( 27697074 )
2016
9
Impulse control disorder in PD: A lateralized monoaminergic frontostriatal disconnection syndrome? ( 27264342 )
2016
10
[A^A^C]-(+)-PHNO PET imaging of dopamine D(2/3) receptors in Parkinson's disease with impulse control disorders. ( 25641350 )
2015
11
Parkinson's disease treatment may cause impulse-control disorder via dopamine D3 receptors. ( 25645960 )
2015
12
Pet killing as a manifestation of impulse control disorder secondary to pramipexol. ( 25768852 )
2015
13
Incident impulse control disorder symptoms and dopamine transporter imaging in Parkinson disease. ( 26534930 )
2015
14
Impulse control disorder manifesting as hidden sexual self-injury. ( 25828732 )
2015
15
Impulse control disorders and punding in Perry syndrome. ( 26411500 )
2015
16
The addiction-related gene ANKK1 in Parkinsonian patients with impulse control disorder. ( 25447970 )
2015
17
Idiopathic Basal Ganglia Calcification Presented with Impulse Control Disorder. ( 26246920 )
2015
18
Impulse control disorder and rapid eye movement sleep behavior disorder in Parkinson's disease. ( 25283069 )
2014
19
Impulse control disorder in patients with Parkinson's disease under dopamine agonist therapy: a multicentre study. ( 24434037 )
2014
20
Dopamine agonist withdrawal syndrome in a patient with restless legs syndrome without impulse control disorder or drug abuse. ( 25362251 )
2014
21
Depression and impulse control disorders in Parkinson's disease: Two sides of the same coin? ( 24239733 )
2014
22
Amantadine and cognitive flexibility: decision making in Parkinson's patients with severe pathological gambling and other impulse control disorders. ( 24971012 )
2014
23
REM sleep behavior disorder: association with motor complications and impulse control disorders in Parkinson's disease. ( 25085747 )
2014
24
Impulse control disorder in a patient on long-term treatment with bromocriptine for a macroprolactinoma. ( 24045609 )
2013
25
Three cases of impulse control disorder in Parkinson's disease patients receiving dopamine replacement therapy. ( 23472375 )
2013
26
Dopamine agonist-induced impulse control disorders in a patient with prolactinoma. ( 23261076 )
2013
27
Major depression after withdrawing dopamine agonists in two patients with restless legs syndrome and impulse control disorders. ( 23714418 )
2013
28
Pathological generosity: An atypical impulse control disorder after a left subcortical stroke. ( 23962063 )
2013
29
Impulse control disorder in a patient with X-linked dystonia-parkinsonism after bilateral pallidal deep brain stimulation. ( 23920134 )
2013
30
The role of self-awareness and cognitive dysfunction in Parkinson's disease with and without impulse-control disorder. ( 23686032 )
2013
31
Dopaminergic influences on executive function and impulsive behaviour in impulse control disorders in Parkinson's disease. ( 23901888 )
2013
32
Zoophilia and impulse control disorder in a patient with Parkinson disease. ( 22057400 )
2012
33
Transdermal rotigotine causes impulse control disorders in patients with restless legs syndrome. ( 22030321 )
2012
34
Impulse-control disorders in gilles de la tourette syndrome. ( 22450610 )
2012
35
Is premature ejaculation an impulse control disorder? ( 22543077 )
2012
36
Comorbid impulse control disorder in bipolar disorder: the role of antidepressants. ( 22423377 )
2012
37
Prevalence and pharmacological factors associated with impulse-control disorder symptoms in patients with Parkinson disease. ( 23123689 )
2012
38
Alexithymia is associated with impulsivity in newly-diagnosed, drug-naA^ve patients with Parkinson's disease: an affective risk factor for the development of impulse-control disorders? ( 23224478 )
2012
39
Role of genetic polymorphisms of the dopaminergic system in Parkinson's disease patients with impulse control disorders. ( 22113132 )
2012
40
Obsessive-compulsive disorder, impulse control disorders and drug addiction: common features and potential treatments. ( 21568361 )
2011
41
The emergence of devastating impulse control disorders during dopamine agonist therapy of the restless legs syndrome. ( 21412200 )
2011
42
Impulse control disorder comorbidity among patients with bipolar I disorder. ( 21683175 )
2011
43
Tourette's disease with impulse control disorder. ( 21431012 )
2011
44
Dermatitis artefacta in a patient affected by impulse control disorder: case report. ( 21489363 )
2011
45
Pathological gambling: an impulse control disorder? Measurement of impulsivity using neurocognitive tests. ( 20803888 )
2010
46
Kleptomania, an unusual impulsive control disorder in Parkinson's disease? ( 20202886 )
2010
47
Swallowing foreign bodies as an example of impulse control disorder in a patient with intellectual disabilities: a case report. ( 20941350 )
2010
48
Impulse control disorder and piribedil: report of 5 cases. ( 19959959 )
2010
49
Parkinsonism and impulse control disorder: presentation of a new progranulin gene mutation. ( 19133655 )
2009
50
Impulse control disorder behaviors associated with pramipexole used to treat fibromyalgia. ( 19241148 )
2009

Variations for Impulse Control Disorder

Expression for Impulse Control Disorder

Search GEO for disease gene expression data for Impulse Control Disorder.

Pathways for Impulse Control Disorder

GO Terms for Impulse Control Disorder

Cellular components related to Impulse Control Disorder according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 endocytic vesicle GO:0030139 8.62 DRD2 DRD3

Biological processes related to Impulse Control Disorder according to GeneCards Suite gene sharing:

(show all 32)
id Name GO ID Score Top Affiliating Genes
1 synapse assembly GO:0007416 9.65 DRD2 SLITRK1
2 circadian regulation of gene expression GO:0032922 9.65 DRD2 DRD3
3 social behavior GO:0035176 9.65 DRD3 DRD4
4 visual learning GO:0008542 9.64 DRD2 DRD3
5 response to cocaine GO:0042220 9.64 DRD2 DRD3
6 negative regulation of protein kinase B signaling GO:0051898 9.63 DRD2 DRD3
7 positive regulation of cytokinesis GO:0032467 9.63 DRD2 DRD3
8 negative regulation of adenylate cyclase activity GO:0007194 9.63 DRD2 DRD3 DRD4
9 negative regulation of blood pressure GO:0045776 9.62 DRD2 DRD3
10 adult behavior GO:0030534 9.62 DRD2 SLITRK1
11 response to morphine GO:0043278 9.61 DRD2 DRD3
12 regulation of dopamine secretion GO:0014059 9.61 DRD2 DRD3
13 response to amphetamine GO:0001975 9.61 DRD2 DRD3 DRD4
14 synaptic transmission, dopaminergic GO:0001963 9.6 DRD2 DRD3
15 behavioral response to ethanol GO:0048149 9.59 DRD2 DRD4
16 prepulse inhibition GO:0060134 9.58 DRD2 DRD3
17 positive regulation of renal sodium excretion GO:0035815 9.58 DRD2 DRD3
18 arachidonic acid secretion GO:0050482 9.58 DRD2 DRD3 DRD4
19 negative regulation of voltage-gated calcium channel activity GO:1901386 9.57 DRD2 DRD4
20 G-protein coupled receptor internalization GO:0002031 9.56 DRD2 DRD3
21 regulation of cAMP metabolic process GO:0030814 9.55 DRD2 DRD3
22 regulation of dopamine uptake involved in synaptic transmission GO:0051584 9.54 DRD2 DRD3
23 behavioral response to cocaine GO:0048148 9.54 DRD2 DRD3 DRD4
24 negative regulation of dopamine receptor signaling pathway GO:0060160 9.52 DRD2 DRD3
25 positive regulation of dopamine uptake involved in synaptic transmission GO:0051586 9.51 DRD2 DRD4
26 dopamine receptor signaling pathway GO:0007212 9.5 DRD2 DRD3 DRD4
27 acid secretion GO:0046717 9.49 DRD2 DRD3
28 regulation of locomotion involved in locomotory behavior GO:0090325 9.48 DRD2 DRD3
29 dopamine metabolic process GO:0042417 9.43 DRD2 DRD3 DRD4
30 negative regulation of protein secretion GO:0050709 9.33 DRD2 DRD3 DRD4
31 adenylate cyclase-inhibiting dopamine receptor signaling pathway GO:0007195 9.13 DRD2 DRD3 DRD4
32 response to histamine GO:0034776 8.8 DRD2 DRD3 DRD4

Molecular functions related to Impulse Control Disorder according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 drug binding GO:0008144 9.43 DRD2 DRD3 DRD4
2 dopamine binding GO:0035240 9.33 DRD2 DRD3 DRD4
3 dopamine neurotransmitter receptor activity, coupled via Gi/Go GO:0001591 9.13 DRD2 DRD3 DRD4
4 dopamine neurotransmitter receptor activity GO:0004952 8.8 DRD2 DRD3 DRD4

Sources for Impulse Control Disorder

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 MedGen
42 MeSH
43 MESH via Orphanet
44 MGI
46 NCI
47 NCIt
48 NDF-RT
51 NINDS
52 Novoseek
54 OMIM
55 OMIM via Orphanet
59 PubMed
60 QIAGEN
65 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....